Lexeo Therapeutics, Inc.
LXEO
$4.84
-$0.12-2.42%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 0.90% | 38.16% | 19.31% | 31.22% | -22.91% |
| Total Depreciation and Amortization | 9.02% | 8.98% | 3.26% | 4.13% | 2.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,103.86% | -26.85% | -22.47% | -28.47% | -110.01% |
| Change in Net Operating Assets | 249.37% | -162.51% | 62.56% | -269.35% | 40.56% |
| Cash from Operations | 35.35% | 2.63% | 29.11% | -65.94% | -35.07% |
| Capital Expenditure | 93.52% | -- | -- | -248.19% | 49.30% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 136.53% | 76.25% | -8.66% | -- | -781,220.00% |
| Cash from Investing | 136.41% | 76.03% | -8.66% | 42,281.93% | -17,869.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -16.39% | 23.90% | -45.69% | 25.23% | -64.86% |
| Issuance of Common Stock | -68.35% | 1,428.24% | 668,482.61% | 246.15% | 1,100.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 88.74% | -- | -- | -- | -10.02% |
| Cash from Financing | -66.56% | 22,190.91% | 148,318.56% | 172.22% | 24,972.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 220.79% | 243.62% | 118.04% | 130.71% | 132.71% |